Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines

Specchia, Giorgina; Buquicchio, Caterina; Pansini, Nicola; Serio, Francesca Di; Liso, Vincenzo; Pastore, Domenico; Greco, Gianpiero; Ciuffreda, Lucia; Mestice, Anna; Liso, Arcangelo

doi:10.1016/j.lab.2005.02.003

Cited by 59 publications

(32 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional smaller studies have also demonstrated correlations between troponin elevations and subsequent LVEF decline. [175][176][177] Troponins may be also be used to identify early cardiac injury in patients undergoing treatment with newer targeted anti-cancer drugs. The largest of these studies, performed in 251 patients with breast cancer treated with trastuzumab, demonstrated that TnI positivity was associated with an increased incidence of cardiac events and lower likelihood of recovery.…”

Section: Figure 8 Speckle-tracking Echocardiographical Images Illustrmentioning

confidence: 99%

Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

Plana

Galderisi

Barac

et al. 2014

Journal of the American Society of Echocardiography

1,238

1,181

View full text Add to dashboard Cite

Section: Figure 8 Speckle-tracking Echocardiographical Images Illustrmentioning

confidence: 99%

Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

Plana

Galderisi

Barac

et al. 2014

Journal of the American Society of Echocardiography

1,238

1,181

View full text Add to dashboard Cite

“…Measurement of these molecules for the prediction of future cardiac toxicity is associated with widely varying sensitivity and specificity [6,7,[19][20][21]. These variations are possibly due to inhomogeneous characteristics of the studies.…”

Section: Discussionmentioning

confidence: 99%

Cardiac troponin T for early detection of cardiotoxicity in breast cancer patients treated with epirubicin

et al. 2009

View full text Add to dashboard Cite

AbstractThe aim of the study was to investigate the role of cTnT for the prediction of long term cardiac dysfunction after epirubicin-containing adjuvant chemotherapy for breast cancer. The study group comprised of 45 patients (all female; mean age 48 ±8 years), treated with epirubicin-containing adjuvant chemotherapy for stage 2 and stage 3 breast cancer. Patients received either 4 cycles of cyclophosphamide plus epirubicin (90 mg/m2) (n=23; stage 2 breast cancer) or 6 cycles of cyclophosphamide plus epirubicin (75 mg/m2) plus fluorouracil (n=18; stage 3 breast cancer). Venous blood samples were drawn, before and 72 hours after, every cycle of chemotherapy for the measurement of cTnT. Cardiac assessment was carried out at baseline and 1 year after chemotherapy by clinical evaluation, electrocardiography, radio-nuclide ventriculography (RNV) and transthoracic echocardiography. All patients remained free of clinical heart failure during the study period. In 26 patients (63%), cTnT was elevated after chemotherapy. Mean left ventricular ejection fraction, assessed by RNV at baseline and one year after chemotherapy, were 61±8% and 56±7% (p<0.0001). The sensitivity and specifity of cTnT for the detection of left ventricular systolic dysfunction at one year were 69% and 39% respectively. Echocardiographic examinations at baseline and one year after chemotherapy revealed a significant decrease in E/A ratio from 1.15±0.3 to 0.9±0.2 in cTnT positive patients, suggesting diastolic dysfunction. In conclusion, elevated serum cTnT levels after epirubicin-containing adjuvant chemotherapy for stage 2 and stage 3 breast cancer, predict future cardiac dysfunction with moderate sensitivity and poor specificity.

show abstract

“…A significant LVEF reduction was observed in TnI positive patients treated with AC for leukemia. (21) In addition, an increased…”

Section: Troponinsmentioning

confidence: 99%

“…Many studies have also elucidated that troponin value can remain elevated for a period ranging from a few hours to several months, after the completion of CT. (19,20,21,28,30) On the other hand, the exact time-point at which a negative troponin value reaches 100% of specificity for no further troponin release cannot yet be defined, (31) therefore, repeated blood samples are required to pick out a possible troponin increase. This represents a possible limitation for using these markers in clinical practice.…”

Section: Troponinsmentioning

confidence: 99%

Using biomarkers and early prophylactic treatment to prevent cardiotoxicity in cancer patients on chemotherapy

Bacchiani

Cardinale

2017

SAHJ

View full text Add to dashboard Cite

Using biomarkers and early prophylactic treatment to prevent cardiotoxicity in cancer patients on chemotherapy goal for both cardiologists and oncologists. The main strategy to prevent clinical cardiotoxicity is early detection and the initiation of prompt prophylactic therapy. EARLY DETECTION OF CARDIOTOXICITY Current approachPeriodic assessment for LVEF is the most widely used non-invasive method for detecting cardiotoxicity LVEF either via echocardiography or multigated acquisition scanning. Although several available guidelines exist none specify how often, by what means or how long cardiac function should be monitored during and after cancer treatment. The recommendations of these guidelines are not consistent and seem to be based on modest evidence. Though LVEF is a crude index of cardiac function, it is relatively insensitive in detecting anticancer drug-induced cardiotoxicity at an early stage. Usually there are compensatory mechanisms in place to ensure normal overall function in a patient despite an initial reduction in myocardial contractility. As a rule no considerable

show abstract

Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines

Cited by 59 publications

References 35 publications

Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

Cardiac troponin T for early detection of cardiotoxicity in breast cancer patients treated with epirubicin

Using biomarkers and early prophylactic treatment to prevent cardiotoxicity in cancer patients on chemotherapy

Contact Info

Product

Resources

About